![]() ![]() The populations for these treatments are often very specific: many drugs are approved for a certain tumor type, specific line of therapy, and/or only in populations with certain biomarkers. ![]() However, getting detailed in this space isn’t always easy. With the tremendous growth in this area and the strong commercial and clinical potential, it’s no wonder that forecasters are keen to develop detailed and accurate forecasts. The number of oncology clinical trials initiated in 2018 increased 27% over the prior year to 1,170, and is up 68% over the past five years. Meanwhile, companies continue to push for further oncology development. Spending on treatment for cancer patients reached nearly $150 billion in 2018, marking the fifth consecutive year of double-digit growth and driven entirely by therapeutic drugs. It’s also one of the most important: oncology assets are an increasingly critical part of company portfolios.Īccording to the 2019 Global Oncology Trends Report by the IQVIA Institute, a record 15 new oncology therapeutics were launched in 2018 across 17 indications. ![]() Oncology is one of the most complicated pharma categories to forecast. ![]()
0 Comments
Leave a Reply. |